Cardio protection in patients at high risk of anthracycline induced cardiotoxicity
Last Updated: Monday, August 28, 2023
Anthracyclines are frequently used with curative intent in breast cancer, and other solid tumors but there’s concern about the potential of anthracycline-related myocardial injury and development of left ventricular dysfunction and heart failure. This review shares evidence for cardioprotective strategies to reduce anthracycline cardiotoxicity in high-risk patients.
Advertisement
News & Literature Highlights